SPACE PEPTIDES PHARMACEUTICAL

PEPTIDE DRUG DISCOVERY (CRO) AND MANUFACTURE (CDMO)

Company introduction

Space Peptides Pharmaceutical AG provides peptide new drug discovery CRO (Contract Research Organization) and CDMO (Contract Development and Manufacture Organization) services. The integrated CRO and CDMO model create innovation in early-stage drug discovery / development.

Our customers range from top ten big pharma, to small- and medium- size biotech companies, to academic institutions.

GDBspace provides new drug discovery services – its unique technology applies the chemical space theory, combined with artificial intelligence, to identify the molecules of interests in a precise and time-efficient manner – hence significantly reducing costs and time.

Space Peptides is a peptide CDMO specialized in Good Manufacture Practice (GMP) grade peptide manufacturing, from discovery, development to commercial use.

Space Peptides Locations

Our Locations

Business Center, Messeturm Basel,
Switzerland

R&D collaboration with Uni. Bern,
Switzerland

Laboratories in Xiamen, China
GMP pilot plant in Xiamen, China (capacity 50kg/year

API Factory in Jiangsu, China
(capacity 1100kg/year, in progress)

Satellite Office, Boston, USA

Satellite Office, San Francisco, USA

Core Team

Switzerland

Dr. Runze He

Chief Executive Officer

Dr. Jingwen Shi

Chief Business Officer

Dr. Sacha Javor

Chief Technology Officer

Dr. Clémence Delalande

Business Development Representative / Sr Scientist

Dr. Ivan Di Bonaventura​

R&D Process Advisor ​

Dr. Thissa Siriwarden​

Sr Scientist R&D process

Amelia Coti

Head of Human Resources

Mengfei Shi

Legal

Yuxiang Zuo

Director of Sales & Marketing

Runquan Li

Director of GMP Manufacturing

Jian Guo

Director of Quality

Liang Kong

Director of Government Affairs

Advisory Board

Prof. Jean-Louis Reymond

Scientific Advisor

Prof. Wenjing Hong

Technology Advisor

Dr. Andreas Schulze

Business Advisor

Dr. Simon Nebel

Business Advisor

Dr. Hongming Chen

Technology Advisor

Bettina Buomberger

Sustainability & Compliance Advisor

Company history

Our history

Spin-off from Prof. Reymond’s group at Uni Bern, Switzerland

2013

Peptide synthesis process development and mid-scale manufacturing pilot plant  (capacity 50kg/yr)

2016

Chemical space theory  applied to peptide drug discovery

2019

Case study: Covid-19 peptide fusion inhibitor

2020

Laboratories for in vitro & in vivo tox, PK studies

2021.04

Opening ceremony of large-scale peptide API manufacture plant (capacity 1100kg/yr)

2021.06

Market Proof-of Concept established with leading brands in key markets

2021.09